Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137839 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
A Phase 2 study of Non-Small Cell Lung Cancer and Adenocarcinoma, sponsored by Pasi A. Janne, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 3
- Study locations
NCT00137839: Completed Phase 2 study of Non-Small Cell Lung Cancer and Adenocarcinoma, sponsored by Pasi A. Janne, MD, PhD.
NCT00137839 is a Phase 2 study of Non-Small Cell Lung Cancer and Adenocarcinoma that has completed, run by Pasi A. Janne, MD, PhD. The registered enrollment target is 84 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137839, a Phase 2 study of Non-Small Cell Lung Cancer and Adenocarcinoma, has completed, sponsored by Pasi A. Janne, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.
Primary Outcome
ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD
Conditions Studied
Interventions
- DRUG Erlotinib
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-11 |
| Est. Completion | 2019-07 |
| Phase | Phase 2 |
What the finished NCT00137839 record still lists
NCT00137839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Erlotinib is the first listed.
NCT00137839 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00137839 about?
NCT00137839 is a clinical study titled "Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung". The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.
What is the current status of trial NCT00137839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2004-11. Estimated completion is 2019-07.
What conditions does trial NCT00137839 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Adenocarcinoma.
What interventions are being tested in trial NCT00137839?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00137839?
This trial is sponsored by Pasi A. Janne, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137839 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00137839's enrollment target sits among peer trials
84 264th of 454 higher than 191 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia